Y mAbs Therapeutics — Q4 2024 Earnings Presentation
21 slides from Y mAbs Therapeutics's earnings presentation, Mar 4, 2025
Slide 1: Q4 & FY 2024 Financial Results and Corporate Update
Q4 & FY 2024 Financial Results and Corporate Update March 4, 2025
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. The forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this pre
Slide 3: Mike Rossi: Q4 and FY 2024 Business Highlights
Mike Rossi President and Chief Executive Officer Q4 and FY 2024 Business Highlights 3
Slide 4: Agenda
Agenda Q4 & FY 2024 Business Highlights 1 Mike Rossi, President and Chief Executive Officer DANYELZA Global Performance 2 Doug Gentilcore, DANYELZA Business Unit Head SADA PRIT Update 3 Natalie Tucker, Radiopharmaceutical Business Unit Head Q4 & FY 2024 Financials, Q1 & FY 2025 Guidance 4 Peter Pfre
Slide 5: Q4 & FY 2024 and Recent Corporate Highlights
Q4 & FY 2024 and Recent Corporate Highlights ✓ FY 2024 Total Revenues of $87.7M, in-line with January preannouncement and within FY 2024 guidance range of between $87M-$95M ✓ DANYELZA anti-GD2 U.S. market share stable at 15%-17% ✓ Ex-U.S. demand continued to grow through partners and NPPs* ✓ Proof-o
Slide 6: Realignment into Business Units Intended to Accelerate Development in Radiopharmaceuticals
Realignment into 2 Business Units Intended to Accelerate Development in Radiopharmaceuticals and Maximize Value of DANYELZA Adding dedicated internal resources, increasing flexibility, and optimizing Expand Radiopharmaceutical Capabilities operations is critical to advancing our Radiopharmaceutical
Slide 7: Doug Gentilcore: DANYELZA Global Performance
Doug Gentilcore DANYELZA Business Unit Head DANYELZA Global Performance 7
Slide 8: DANYELZA Global Commercial Update
Q4 & FY 2024 DANYELZA Global Commercial Update • Q4 2024 Total DANYELZA Net Product Revenues of $24.5M, 5% YoY • Q4 2024 ex-U.S. DANYELZA Net Product Revenues of $7.7M, 78% YoY • 69 U.S. accounts* since initial launch; 11 new accounts added in FY 2024 • DANYELZA remains a leading therapy in U.S.
Slide 9: Natalie Tucker: SADA PRIT Update
Natalie Tucker Radiopharmaceutical Business Unit Head SADA PRIT Update 9
Slide 10: GD2-SADA Phase 1 Clinical Trial (Trial 1001): Part A Closed
GD2-SADA Phase 1 Clinical Trial (Trial 1001): Part A Closed Pretargeted theranostic platform for treatment of GD2 positive solid tumors Trial Overview Part A Determine optimal, well- tolerated GD2-SADA protein Part A Data Anticipated to be • Solid tumors: SCLC, dose and dosing interval Presented in
Slide 11: CD38-SADA Phase 1 Clinical Trial (Trial 1201): Trial Design
CD38-SADA Phase 1 Clinical Trial (Trial 1201): Trial Design Pretargeted theranostic platform for treatment of CD38 positive hematological tumors Inclusion Criteria Part A Part B N = 12 – 15 N = 12 – 15 • R/R non-Hodgkin TRIAL UPDATE Lymphoma and ineligible/ exhausted standard DESIGN CD38-SADA protei
Slide 12: Anticipated GD2-SADA Q2 2025 Data Readout
Anticipated GD2-SADA Q2 2025 Data Readout Q2 2025 Planned Trial: Ongoing Trial 1001 (GD2-SADA) Platform Optimization Bridge to 1001 Part B Phase 1: Optimization Workstreams Evaluate Optimized GD2-SADA Part A Data Readout Underway Platform • Optimize chelator • Current 1001 IND with protocol ✓ Safety
Slide 13: Y-mAbs' Comprehensive Radiopharmaceutical Target Identification Process
Y-mAbs’ Comprehensive Radiopharmaceutical Target Identification Process Next Cohort of Potential High-Value Oncology Targets for Development with SADA PRIT Selection to determine suitability Prioritized target archetypes for Targets diversified across tumor types, but also for targeting with SADA PR
Slide 14: Peter Pfreundschuh: Financials and Q1 & FY 2025 Guidance
Peter Pfreundschuh Chief Financial Officer Q4 & FY 2024 Financials and Q1 & FY 2025 Guidance 14
Slide 15: Key Financial Highlights: Revenue
Key Q4 & FY 2024 Financial Highlights Revenue Three months ended Dec 31, 12 months ended Dec 31, 2024 2023 2024 2023 Net product revenue $24.5 M $23.4 M Net product revenue $85.2 M $84.3 M License revenue $2.0 M – License revenue $2.5 M $0.5 M Total revenue $26.5 M $23.4 M Total revenue $87.7 M $84.
Slide 16: Key Financial Highlights: Operating Expenses
Key Q4 & FY 2024 Financial Highlights Operating Expenses Three months ended Dec 31, 12 months ended Dec 31, 2024 2023 2024 2023 License royalties $0.2 M – License royalties $0.25 M $0.05 M Research & development $12.2 M $13.4 M Research & development $49.0 M $54.2 M Selling, general & admin $12.4 M
Slide 17: Key Financial Highlights: Net Loss
Key Q4 & FY 2024 Financial Highlights Net Loss Three months ended Dec 31, 12 months ended Dec 31, 2024 2023 2024 2023 Net loss $(6.8) M $(1.0) M Net loss $(29.7) M $(21.4) M Net loss per basic, diluted share $(0.15) $(0.02) Net loss per basic, diluted share $(0.67) $(0.49) 17
Slide 18: Key Financial Highlights: Responsible stewards of capital
Key Q4 & FY 2024 Financial Highlights Responsible stewards of capital As of 12 months ended Dec 31, Dec 31, 2024 Dec 31, 2023 2024 2023 Cash and cash equivalents $67.2 M $78.6 M Cash use $11.4 M $27.1 M Anticipated cash runway Total Annual Cash into 2027* Investment 58% YoY *This estimate reflects
Slide 19: Financial Guidance for Q1 and Full Year 2025
Financial Guidance for Q1 and Full Year 2025 FY 2024 Total Expected Revenues: $75 million to $90 million Q1 2024 Total Expected Revenues: $18 million to $21 million Total Expected Operating Costs and Expenses: $116 million to $121 million Total Expected Annual Cash Investment: $25 million to $30 mil
Slide 20: Q&A
Q&A Mike Rossi Doug Gentilcore President and DANYELZA Business Chief Executive Officer Unit Head Natalie Tucker Peter Pfreundschuh Radiopharmaceutical Chief Financial Officer Business Unit Head 20
Slide 21: Thank You
Thank You